Novo Nordisk A/S (NYSE:NVO) Shares Acquired by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 7.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,327 shares of the company’s stock after purchasing an additional 1,302 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Novo Nordisk A/S were worth $1,576,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James & Associates grew its stake in Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC grew its stake in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the last quarter. International Assets Investment Management LLC grew its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. LPL Financial LLC grew its stake in Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after acquiring an additional 47,496 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Up 8.4 %

Shares of NVO stock opened at $87.94 on Monday. The firm has a market cap of $394.65 billion, a P/E ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm’s 50-day simple moving average is $95.35 and its 200-day simple moving average is $114.99.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.